Completed PHASE2 INTERVENTIONAL 3-arm NCT03587766

Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease (FEXI12)

Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease

Sponsor: Drugs for Neglected Diseases

Conditions Chagas' Disease (Chronic) Nos

Interventions Fexinidazole Placebo Oral Tablet

Updated 6 times since 2018 Last updated: Sep 21, 2020 Started: Nov 13, 2017 Primary completion: Dec 19, 2018 Completion: Aug 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chagas' Disease (Chronic) Nos and is currently completed. Drugs for Neglected Diseases leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Aug 2020 — Oct 2020 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Aug 2018 — Aug 2020 [monthly]

Recruiting PHASE2

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Drugs for Neglected Diseases

Data source: Drugs for Neglected Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain